Careers  |  Sign In  |  Register  |   Twitter

Amgen Shows Positive Outcomes for New Cholesterol Drug

Reuters reports that Amgen Inc. has shown that their new drug, from a new class of inhibitors called PCSK9, is effective in lower levels of low-density lipoproteins (LDL). The clinical trial was the first of its kind to test the drug over a 52 week period. One thousand, one hundred and four patients were injected with a 420 mg dose of the drug, evolocumab, every month over the period of a year. At the end of the study, patients who got the evolocumab injections showed a 52% reduction in LDL levels compared to those receiving statin treatment. Additionally, high-density lipoprotein (HDL) levels rose by 9% and adverse side-effects did not differ significantly from those that occurred in the statin group. “An FDA official last week said the agency might be willing to approve the PCSK9 drugs without outcomes data if they did not show any unexpected toxicities.”

Read the article published by Reuters.